open access

Vol 48, No 4 (2017)
Prace poglądowe / Reviews
Published online: 2017-10-01
Submitted: 2017-10-15
Get Citation

Optimizing strategies lenalidomide therapy in the treatment of multiple myeloma

Agnieszka Szymczyk, Iwona Hus1
DOI: 10.1016/j.achaem.2017.10.002
·
Acta Haematol Pol 2017;48(4):282-290.
Affiliations
  1. Samodzielna Pracownia Transplantologii Klinicznej, Uniwersytet Medyczny w Lublinie, Polska

open access

Vol 48, No 4 (2017)
Prace poglądowe / Reviews
Published online: 2017-10-01
Submitted: 2017-10-15

Abstract

The introduction of new drugs (immunomodulators, proteasome inhibitors) into the treatment of multiple myeloma (MM) has contributed to the increase in response rates and also to a significant prolongation of overall survival, allowing multiple myeloma to become a chronic disease. Lenalidomide is an immunomodulatory agent, more effective and less toxic than the first immunomodulatory drug introduced into MM therapy - thalidomide. Lenalidomide should be given continously and longer treatment is associated with increased response rates and improved quality of response. That is why prophylaxis and proper management of adverse events is extremely important for continuation of the therapy. The dose of lenalidomide should be modified in patients with renal failure and cytopenias, also effective venous thromboembolism (VTE) is required. This article describes optimization of lenalidomide therapy with regard to the most common clinical problems.

Abstract

The introduction of new drugs (immunomodulators, proteasome inhibitors) into the treatment of multiple myeloma (MM) has contributed to the increase in response rates and also to a significant prolongation of overall survival, allowing multiple myeloma to become a chronic disease. Lenalidomide is an immunomodulatory agent, more effective and less toxic than the first immunomodulatory drug introduced into MM therapy - thalidomide. Lenalidomide should be given continously and longer treatment is associated with increased response rates and improved quality of response. That is why prophylaxis and proper management of adverse events is extremely important for continuation of the therapy. The dose of lenalidomide should be modified in patients with renal failure and cytopenias, also effective venous thromboembolism (VTE) is required. This article describes optimization of lenalidomide therapy with regard to the most common clinical problems.

Get Citation

Keywords

Multiple myeloma; Lenalidomide; Renal failure; Thrombocytopenia; Neutropenia; Venous thromboembolism

About this article
Title

Optimizing strategies lenalidomide therapy in the treatment of multiple myeloma

Journal

Acta Haematologica Polonica

Issue

Vol 48, No 4 (2017)

Pages

282-290

Published online

2017-10-01

DOI

10.1016/j.achaem.2017.10.002

Bibliographic record

Acta Haematol Pol 2017;48(4):282-290.

Keywords

Multiple myeloma
Lenalidomide
Renal failure
Thrombocytopenia
Neutropenia
Venous thromboembolism

Authors

Agnieszka Szymczyk
Iwona Hus

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl